In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists lower the occurrence of major adverse cardiovascular events by 17% compared to no such treatment, with an absolute reduction of 2.12% over three years.
See the scientific wording
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) by 17% in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, based on pooled data from seven randomized controlled trials involving 38,642 patients, with an absolute risk reduction of 2.12% over three years and a number needed to treat of 47 to prevent one MACE event.
Very strong evidence
One good-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis
For people with type 2 diabetes and existing heart disease, taking GLP-1 drugs lowers the chance of heart attacks or strokes by about 1 in 47 over three years — and this study proves it by looking at thousands of patients.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
GLP-1 receptor agonists slow the buildup of fatty plaques in arteries and make existing plaques less likely to rupture, which prevents heart attacks and strokes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists lower the occurrence of major adverse cardiovascular events by 17% compared to no such treatment, with an absolute reduction of 2.12% over three years.
Mechanism
1 studyGLP-1 receptor agonists make dangerous artery plaques less likely to burst by calming inflammation and strengthening the protective cap over them. This prevents clots from forming and causing heart attacks or strokes.
GLP-1 receptor agonists slow the buildup of fatty plaques in arteries and make existing plaques less likely to rupture, which prevents heart attacks and strokes.
GLP-1 receptor activation on vascular endothelial cells reduces expression of adhesion molecules and chemokines, decreasing monocyte recruitment into the arterial wall
GLP-1 receptor signaling in macrophages within atherosclerotic plaques shifts polarization from pro-inflammatory M1 to anti-inflammatory M2 phenotype, reducing cytokine release and necrotic core expansion
GLP-1 receptor agonism enhances collagen deposition by vascular smooth muscle cells, thickening the fibrous cap over atherosclerotic lesions
Reduced plaque inflammation and increased fibrous cap thickness lower the likelihood of plaque rupture and subsequent thrombus formation
Evidence from Studies
Supporting (1)
Community contributions welcome
For people with type 2 diabetes and existing heart disease, taking GLP-1 drugs lowers the chance of heart attacks or strokes by about 1 in 47 over three years — and this study proves it by looking at thousands of patients.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of GLP-1 Receptor Agonists on MACE in Type 2 Diabetes with ASCVD
Systematic review and meta-analysis of all randomized controlled trials comparing GLP-1 receptor agonists to placebo or standard care in adults with type 2 diabetes and established ASCVD, with MACE as the primary outcome over minimum three-year follow-up
Double-Blind Placebo-Controlled Trial of Liraglutide vs Placebo for MACE Prevention in Type 2 Diabetes with ASCVD
Randomized, double-blind, placebo-controlled trial in adults with type 2 diabetes and established ASCVD, comparing a GLP-1 receptor agonist to placebo, with MACE as the primary endpoint over three years
Prospective Cohort Study of GLP-1 Receptor Agonist Use and MACE Incidence in Real-World Type 2 Diabetes with ASCVD
Prospective cohort study following adults with type 2 diabetes and ASCVD who initiate GLP-1 receptor agonists versus those who do not, with MACE as the primary outcome over three years, adjusting for confounders
Case-Control Study of Prior GLP-1 Receptor Agonist Exposure in Patients with vs without MACE in Type 2 Diabetes and ASCVD
Case-control study comparing patients with type 2 diabetes and ASCVD who experienced MACE (cases) to matched controls without MACE, assessing prior exposure to GLP-1 receptor agonists
Cross-Sectional Analysis of GLP-1 Receptor Agonist Use and Prevalence of MACE in Type 2 Diabetes with ASCVD
Cross-sectional analysis of a representative sample of adults with type 2 diabetes and ASCVD, measuring current GLP-1 receptor agonist use and presence of MACE at one time point